CD38 and B-cell chronic lymphocytic leukemia: In a plasmacytoma MM model and disseminated MM model, ricolinostat combined with bortezomib significantly inhibited tumor growth and extended OS.665 It also increased sensitivity to daratumumab by upregulating CD38 expression in MM cells.666 A similar antitumor effect was also found in lymphoma.667 A combination treatment of ricolinostat with an immune checkpoint inhibitor and ibrutinib was effective in CLL and FL, respectively, in vitro and in vivo.668,669 Several clinical trials are examining its effect in R/R MM, CLL, and lymphoma.